More FDA Oversight Of DTC Ads May Be Needed To Curtail Misleading Claims, Study Argues

Clearer US guidance on DTC TV advertising and stronger enforcement would help reduce misleading claims and encourage drug makers to include more qualitative benefit/risk information in ads, according to a new study from Yale University researchers published in the Journal of General Internal Medicine.